Ozempic Makes Billions. Its Canadian Patent Fee Was $450. #Shorts

About this episode

Novo Nordisk's core semaglutide patent in Canada is gone. Not beaten in court: it lapsed after the 2019 renewal fee, CA$250 or CA$450 with the late fee, went unpaid. Novo told Fortune there was no mistake and that its IP decisions are "carefully considered at a global level." The patent would have expired in March 2026 anyway, but it took a two-year extension certificate (to March 2028) down with it. In April 2026, Canada became the first G7 country to approve a generic semaglutide. In the U.S., the core patent runs to December 2031. The full story is on the channel. Patents shown: CA 2,601,784 (data retypeset from the Canadian Patents Database) · US 8,129,343 (claim 1 structure, term extension certificate) Credits Patent claim structure and certificates: USPTO. Canadian patent and register data retypeset from public records. Illustrations, music and sound design: original. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Not affiliated with Novo Nordisk, Sandoz, Apotex or Dr. Reddy's. Not medical, pricing or legal advice. Strategy education from ipCapital Group. Strategy education, not legal advice. ipCapital Group. #Ozempic #Patents #Semaglutide #IntellectualProperty #Canada